Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04-304 ...

Revenue Performance - Revenue for Q3 FY2024 was $173 million, a 4% increase year-over-year, with organic revenue growth of 5%[4] - Sample Management Solutions revenue reached $81 million, up 7% year-over-year, driven by higher revenues in Sample Repository Solutions and Core Products[4] - B Medical Systems revenue was $29 million, reflecting a 7% year-over-year increase, with organic revenue growth of 8% attributed to additional cold chain solutions orders[4] - Total revenue for June 30, 2024, was $172,809 million, a 4.3% increase from $165,948 million in the same period of 2023[18] - Revenue for the quarter ended June 30, 2024, was $81 million, a 7% increase from $75 million in the same quarter of 2023[41] - Organic revenue for the nine months ended June 30, 2024, was $231 million, reflecting a 4% increase from $222 million in the same period of 2023[42] Profitability Metrics - Adjusted EBITDA for continuing operations was $18 million, with an adjusted EBITDA margin of 10.3%, an improvement of 260 basis points year-over-year[7] - Non-GAAP diluted EPS was $0.16, compared to $0.13 in the same quarter last year[7] - Operating loss was $15 million, with an operating margin of (8.5%), an improvement of 100 basis points year-over-year[5] - Gross profit for the quarter was $69,056 million, compared to $68,005 million in the previous year, reflecting a slight increase[18] - Non-GAAP adjusted net income from continuing operations was $8,739,000, or $0.16 per diluted share, compared to $2,797,000, or $0.05 per diluted share, in the prior quarter[26] - Non-GAAP adjusted net income from continuing operations was $12,951,000 for the nine months ended June 30, 2024, slightly down from $13,130,000 in the prior year[27] Cash and Assets - The company ended the quarter with cash, cash equivalents, restricted cash, and marketable securities totaling $754 million[8] - Cash and cash equivalents decreased to $336,543 million from $678,910 million year-over-year[20] - Total assets decreased to $2,323,295 million from $2,885,720 million year-over-year[20] - Total cash, cash equivalents, and restricted cash decreased to $346,863,000 as of June 30, 2024, down from $684,045,000 at the end of the previous period[24] Expenses and Losses - Operating expenses were $84 million, flat year-over-year, driven by lower research and development and selling, general and administrative expenses[5] - Net loss for the quarter was $(6,582) million, compared to $(1,470) million in the same period last year[18] - Basic net loss per share was $(0.12) for the quarter, compared to $(0.04) in the same quarter of 2023[18] - The company reported a net loss of $159,186,000 for the nine months ended June 30, 2024, compared to a net loss of $17,632,000 for the same period in 2023[23] - The company incurred $115,975,000 in impairment of goodwill and intangible assets during the nine months ended June 30, 2024, with no such charges in the previous year[23] Shareholder Actions - The company repurchased 4.2 million shares for $225.9 million in Q3, with a total of 25.1 million shares repurchased for $1.25 billion under the 2022 Repurchase Authorization[9] Guidance and Future Outlook - For FY2024, total revenue guidance is lowered to $652 to $658 million, while non-GAAP diluted EPS guidance is raised to a range of $0.30 to $0.36[10] - The company anticipates long-term benefits from transformation costs aimed at cost reduction and productivity improvement, which do not meet the definition of restructuring charges[34] - The company anticipates long-term benefits from its transformation plan, which includes significant changes to processes and technology[40] Transformation and Costs - Transformation costs for the nine months ended June 30, 2024, amounted to $8,742,000, reflecting strategic projects aimed at long-term benefits[27] - Transformation costs for B Medical Systems amounted to $2,783 thousand, representing 9.8% of revenue for the quarter ended June 30, 2024[32] - Transformation costs for the nine months ended June 30, 2024, amounted to $3,365 thousand, compared to no such costs in the same period of 2023[40] Impairment and Restructuring - The company reported a restructuring charge of $10,528 thousand for the nine months ended June 30, 2024, compared to $3,773 thousand in the same period of 2023[40] - Impairment of goodwill and intangible assets for the nine months ended June 30, 2024, was $115,975 thousand, indicating significant asset write-downs[40]

BURLINGTON, Mass., Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2024.Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 173 $ 159 <td ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Azenta (AZTA) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the othe ...

BURLINGTON, Mass., July 24, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes.The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay ...

Azenta will provide proteomics technology profiling on up to 20,000 individuals.BURLINGTON, Mass., July 22, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced its participation in the FinnGen project, a large-scale research initiative at the forefront of personalized medicine in Finland. The FinnGen project is a pioneering endeavor that has collected and is currently analyzing genomic and health data from a cohort of 500,000 Finnish biobank participants.In collaboration with the University of ...

Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries BURLINGTON, Mass., June 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn's & Colitis Foundation (the "Foundation") as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and su ...

BURLINGTON, Mass., May 23, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on Wednesday, June 5, 2024, which includes a presentation beginning at 11:00 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Azenta Life SciencesAzenta, Inc. (Nasdaq: AZT ...

Robotics and automation go hand in hand. Inflationary pressures have been plaguing both consumers and business owners. This has lead to there now being several robotics stocks to sell. Over the last several years, not only did prices increase in certain commodities, but the U.S. labor market has also experienced high relative wage gains, particularly in the services sector. One way to businesses have chosen to protect themselves from inflation has been to embrace automation. The advent of advanced artificia ...

"We're thrilled to open our Oxford laboratory, which allows us to bring state-of-the-art NGS technology to UK researchers," said Dr Ginger Zhou, President of Azenta's Multiomics business unit.  "This new facility not only strengthens our global footprint but also offers researchers access to local experts and cutting-edge resources. The Oxford team comprises some of the best minds in the field, all with deep roots in the local scientific community." The opening event, held on April 25, 2024, featured a ribb ...